Takahiro Tsushima - Concepedia

Author

Takahiro Tsushima

Shizuoka Cancer Center ORCID

Also Known As

T Tsushima, T. TSUSHIMA, T. Tsushima, TAKAHIRO TSUSHIMA, Tadahiko TSUSHIMA, Takahiro Tsushima, Tsushima, Takahiro

249

Publications

4.6K

Citations

H-Index

Concepts

All Affiliations

Shizuoka Cancer Center National Cancer Center Hospital East Aichi Cancer Center Japanese Foundation For Cancer Research Keio University

About

Takahiro Tsushima is an author at Shizuoka Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	45	2.6K
2	Health Sciences	9	9	240
3	Public Health	3	3	415
4	Biochemistry	3	3	88
5	Natural Sciences	2	2	65

Takahiro Tsushima

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial Toshihiro Kudo, Yasuo Hamamoto, Ken Kato, The Lancet Oncology Surgical OncologyEsophageal CancerNivolumab TreatmentGastrointestinal OncologyMedicine	2017	378
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1 Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa, Esophagus EpidemiologyPart 1EsophagusHealth PolicyGastrointestinal Oncology	2023	345
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Kei Muro, Florian Lordick, Takahiro Tsushima, Annals of Oncology	2018	284
Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) K. Yamazaki, Michitaka Nagase, H Tamagawa, Annals of Oncology Gastrointestinal OncologyMedicinePharmacologyColorectal CancerPathology	2016	274
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS Kei Muro, Eric Van Cutsem, Yukiya Narita, Annals of Oncology	2018	214
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study Yasutoshi Kuboki, Tomohiro Nishina, Eiji Shinozaki, The Lancet Oncology Phase 1/2Gastrointestinal OncologyMedicineColorectal CancerC-task Force	2017	171
Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 2 Yuko Kitagawa, Ryu Ishihara, Hitoshi Ishikawa, Esophagus EsophagusEsophageal CancerGastrointestinal OncologyPart 2Medicine	2023	168
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors Toshihiko Doi, Kei Muro, Hiroshi Ishii, Clinical Cancer Research	2019	145
Comprehensive registry of esophageal cancer in Japan, 2015 Masayuki Watanabe, Yasushi Toh, Ryu Ishihara, Esophagus	2022	96
Risk Factors for Esophageal Fistula Associated With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Cancer Takahiro Tsushima, Junki Mizusawa, Kazuki Sudo, Medicine	2016	82

Page 1